PRODUCTS

Restylane logo
Macrolane logo
Deflux logo
Durolane logo
Solesta logo

Q-MED AB
SEMINARIEGATAN 21
752 28 UPPSALA, SWEDEN
Phone: +46-(0)18-474 90 00
Fax: +46-(0)18-474 90 01
E-mail: info@q-med.com

Contact information

INNOVATIVE ESTHETICS AND HOSPITAL HEALTHCARE

Q-Med is a medical device Group that primarily develops, manufactures, markets and sells medical implants.

Esthetics

Q-Med develops products that improve the appearance. When someone experiences a heightened sense of well-being, greater self-esteem or a greater quality of life with the aid of our products, that is beauty for us.

Hospital healthcare

Several of Q-Med's products have been the first on the market. Most of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.

The company today has approximately 650 co-workers in 20 countries, with almost 400 at the company's head office and production facility in Uppsala. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med's interim report January-September 2010

Q-Med's interim report January-September will be released on October 22, 2010.

 


New CEO and new Chairman of the Board at Q-Med AB

Uppsala September 1, 2010

Bengt Ågerup leaves his position as CEO of Q-Med. The Board has appointed Maria Carell as his successor, as was presented in a press release on April 27, 2010.

Anders Milton, who has been a member of
Q-Med's Board since 1997 and Chairman of the Board since 2009, has at his own request resigned as Chairman of the Board but is staying on as a member of the Board. The Board has appointed Bengt Ågerup as the new Chairman of the Board up until the next Annual General Meeting.

Read more >>


THE Q-MED SHARE

QMED 09/09/2010 17:29:48 0% 0 sek, Vol: 92,883
Last: 65.00 sek High: 66.00 sek Low: 64.00 sek
The Q-Med share

Press releases


Press releases

Reports


Financial reports

Sales development